- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02383407
Low Frequency Electrical Stimulation of the Fornix in Intractable Mesial Temporal Lobe Epilepsy (MTLE) (MTLE-DBS)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Low frequency stimulation is an attractive, uninvestigated method for treatment of intractable epilepsy. Preliminary animal and human data suggest safety and remarkable efficacy of Low frequency stimulation (LFS) in epilepsy. In addition, the duty cycle of LFS is very low, implying less electric current injection, with less charge density on the target tissue and electrodes, and longer battery life. The current project is a classic translational, single-blinded, randomized research project, demonstrating a clear path from the laboratory to bedside. If successful, this new therapy will be of great value to patients with medically and surgically intractable Mesial Temporal Lobe Epilepsy (MTLE).
The study is expected to last approximately 5 years, from enrollment of the first patient to completion of the final subject, taking into consideration attrition and otherwise-eligible subjects who will not elect to participate. Once the study is completed, and enrolled participants have completed all required elements of the protocol, a final report will be submitted to the FDA. Participants may also discontinue their participation in the study, if they wish, at any time.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Mohamad Z. Koubeissi, MD
- Phone Number: 202-741-2533
- Email: mkoubeissi@mfa.gwu.edu
Study Locations
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20037
- GW Medical Faculty Associates
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants are between the ages of 18 -65 years of age
- Participants must have had a non-invasive video-EEG monitoring revealing seizure semiology and ictal EEG consistent with unilateral or bilateral MTLE
- Participants must have tried and failed two trials of antiepileptic drugs (AEDs)
- Participants may have lesional or non lesional hippocampi, as evidenced by brain MRI acquired within the previous two years
- Participants are prescribed and taking 1-4 AEDs at the time of study entry
- Study participants will have intractable (MTLE) with a seizure frequency of at least 1/month averaged over the preceding 6 months prior to enrollment, including maximum seizure-freedom periods of no more than 60 days.
- Participants must have a platelet count greater than 125,000 per cubic millimeter and prothrombin time (PT) and activated partial thromboplastin time (aPTT) within normal limits at the visit prior to surgery
Exclusion Criteria:
- Progressive neurological or medical diseases, such as brain tumors or neurodegenerative disease or cancer
- Non-compliance with antiepileptic medications as demonstrated by the medical record
- Any conditions interfering with electrode implantation
- Any non-epileptic seizures
- Inability or unwillingness to complete neuropsychological tests or complete seizure diaries
- Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements
- Pregnant, or planning to become pregnant*
- Participation in another research trial where the participant was treated with another investigational drug or device within 30 days prior to enrollment of study
- Intelligence Quotient showing a general ability Quotient of less than 70. The score excludes the contribution of working memory and processing speed (which are areas of cognitive functioning that are vulnerable to numerous influences including seizures and fatigue and effects of AEDs)
- Inability or unwillingness of individual to give written informed consent
- Participants who have changes to their antiepileptic medications during the baseline phase (as they will need to repeat the baseline phase)
- Subjects with history of status epilepticus within the preceding year
- History of psychiatric illness necessitating hospitalizations
- Subjects who have any of the following implanted devices: aneurysm clips, cardiac pacemaker or defibrillator, cochlear implant, spinal cord, DBS, or vagal nerve stimulator
Co-morbid conditions that would interfere with study stimulation activities or response to treatment, which may include:
- Neoplasm with life expectancy < 5 years
- Severe chronic pulmonary disease
- Local, systemic acute or chronic infectious illness
- Life threatening cardiac arrhythmias
- Severe collagen vascular disorder
- Kidney failure or other major organ system failures
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Stimulation group 2 Hz
Patient will be randomized to a stimulation group of 2 Hz using Medtronic deep brain stimulation device
|
|
Experimental: Stimulation group 5 Hz
Patient will be randomized to a stimulation group of 5 Hz using Medtronic deep brain stimulation device
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and Tolerability of Low Frequency Stimulation of the Fornix With Regards to Memory Function
Time Frame: 1 year
|
The primary outcome is safety and tolerability of LFSF in participants with intractable MTLE with regards to memory function.
The number of participants listed are those who had a significant changes in RAVLT score.
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Psychiatric Health (Effects of LFS on Psychiatric Symptoms Using Standardized Measures That Are Known to be Sensitive to Changes to Surgical Treatment of TLE)
Time Frame: 1 year
|
Since LFSF is expected to activate limbic structures, we will assess the effects of LFS on psychiatric symptoms using standardized measures that are known to be sensitive to changes to surgical treatment of TLE.
The number of participation listed are those who had a significant change in anxiety, depression, or suicidality based on a qualitative overview of the psychiatric assessments performed preoperatively and postoperatively.
|
1 year
|
To Assess if Electrode Implantation in the Fornix is Feasible as is Done in Patients With Parkinson's Disease.
Time Frame: 1 year
|
The DBS leads are routinely implanted for patients with Parkinson's disease.
Thus, we planned to implant Model 3389 DBS leads using the same technique of stereotactic implantation.
A secondary aim of this trial is to standardize the implantation, the evoked potential and electric current determination procedures in preparation for a large-scale phase III trial.
The number of participants with the outcome measure are those in whom bilateral hippocampal CCEPs were consistently present.
|
1 year
|
Effect on Seizure Frequency
Time Frame: 1 year
|
Seizure reduction: Subjects underwent implantation of pulse generators and long-term low-frequency stimulation with mean monthly seizures during blinded phase
|
1 year
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 111239
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mesial Temporal Lobe Epilepsy
-
The University of Texas Health Science Center,...National Institute of Neurological Disorders and Stroke (NINDS)Recruiting
-
Emory UniversityTerminated
-
uniQure France SASRecruitingMesial Temporal Lobe EpilepsyUnited States
-
Neurona TherapeuticsCalifornia Institute for Regenerative Medicine (CIRM)RecruitingMesial Temporal Lobe Epilepsy With Hippocampal SclerosisUnited States
-
National Institute of Mental Health (NIMH)Completed
-
National Institute of Neurological Disorders and...CompletedEpilepsy | Temporal LobeUnited States
-
University of Southern CaliforniaRecruiting
-
University Hospital, MontpellierCompleted
-
Przemyslaw KunertNaoX Technologies; Warsaw Medical University Clinical Center; Departments and...Not yet recruitingEpilepsy | Drug Resistant Epilepsy | Focal EpilepsyPoland
-
Zealand University HospitalUNEEG Medical A/S; Technical University of DenmarkCompleted
Clinical Trials on Medtronic Deep Brain Stimulation
-
Butler HospitalMedtronicCompletedObsessive-Compulsive DisorderUnited States
-
University of FloridaNational Institute of Neurological Disorders and Stroke (NINDS); MedtronicActive, not recruiting
-
Hospital San Carlos, MadridCompletedObsessive-Compulsive Disorder
-
Massachusetts General HospitalActive, not recruitingObsessive Compulsive DisorderUnited States
-
Butler HospitalMedtronicCompleted
-
Johns Hopkins UniversityRecruitingTourette SyndromeUnited States
-
Hadassah Medical OrganizationCompleted
-
University of California, San FranciscoCompleted
-
University Hospital TuebingenMedtronicCompletedCombined STN/SNr-DBS for the Treatment of Refractory Gait Disorders in Parkinson's Disease (STN/SNr)Parkinson's DiseaseGermany
-
Johns Hopkins UniversityNational Institute of Mental Health (NIMH)RecruitingTreatment-resistant SchizophreniaUnited States